Almirall enters partnership with Inserm Transfert to research vitiligo
A partnership between the Spanish biotech firm and the private subsidy of French public research organization Inserm will focus on finding treatment options for the chronic skin condition vitiligo.
by andreas lønstrup, translated by daniel pedersen
Spanish skin health firm Almirall has entered a licensing and research collaboration with Inserm Transfers, a private subsidiary of Inserm, which is the French National Institute of the Health and Medical Research, the company reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
